BioCryst to Present at Upcoming Investor Conferences

Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq:BCRX) announces its participation in two upcoming virtual healthcare conferences. The first is the Cowen 41st Annual Healthcare Conference on March 4, 2021, at 12:10 p.m. ET, followed by the Barclays Annual Healthcare Conference on March 11, 2021, at 8:00 a.m. ET. Interested investors can access live audio webcasts and replays via the investors section of BioCryst’s website.

BioCryst focuses on developing novel oral medicines for rare diseases, with key products like ORLADEYO™ and RAPIVAB® for treating various conditions.

RESEARCH TRIANGLE PARK, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Cowen 41^st Annual Healthcare Conference on Thursday, March 4, 2021 at 12:10 p.m. ET and the Barclays Annual Healthcare Conference on Thursday, March 11, 2021 at 8:00 a.m. ET. Both conferences are being held as virtual events.

Links to a live audio webcast and replay of these presentations may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States and Japan for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in the European Union. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB^® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Contact:
Investors
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com

FAQ

When will BioCryst Pharmaceuticals present at the Cowen Healthcare Conference?

BioCryst Pharmaceuticals will present at the Cowen 41st Annual Healthcare Conference on March 4, 2021, at 12:10 p.m. ET.

What date is BioCryst's presentation at the Barclays Healthcare Conference?

BioCryst Pharmaceuticals will present at the Barclays Annual Healthcare Conference on March 11, 2021, at 8:00 a.m. ET.

How can I listen to BioCryst's conference presentations?

You can access live audio webcasts of BioCryst's presentations in the Investors section of their website.

What products does BioCryst Pharmaceuticals focus on?

BioCryst develops treatments for rare diseases, including ORLADEYO™ and RAPIVAB®.

What is the stock symbol for BioCryst Pharmaceuticals?

The stock symbol for BioCryst Pharmaceuticals is BCRX.